TG4001

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

By nh|2019-11-05T09:54:59+01:00September 30th, 2019|Press release, TG4001, TG4001|Comments Off

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al. ESMO 2019 Download the poster [...]

By Lucie Larguier|2019-10-01T17:34:45+02:00September 30th, 2019|Publication, TG4001|Comments Off

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane M. Harper, et al. Gynecologic Oncology, April 2019 - [...]

By nh|2019-07-01T11:55:19+02:00April 18th, 2019|Publication, TG4001|Comments Off